Prophylaxis of post-myocardial infarction dysrhythmias by long-term timolol therapy

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute myocardial infarction (AMI) poses a significant risk of cardiac arrhythmias.
• Early identification and management of arrhythmias are crucial in AMI patients.

Purpose of the Study:

• To evaluate the antiarrhythmic efficacy of early timolol maleate treatment in patients with acute myocardial infarction.
• To assess the impact of timolol on ventricular premature complexes (VPCs), supraventricular complexes (SVCs), and QRS duration.

Main Methods:

• A randomized controlled trial involving 94 patients with acute myocardial infarction.
• Comparison of early timolol maleate treatment versus placebo.
• Monitoring of VPC rates, couplets, runs, and early-cycle VPCs/SVCs.
• Assessment of QRS duration and adverse effects.

Main Results:

• No significant differences in mean/peak hourly VPC rates, couplets, or runs between timolol and placebo groups early in treatment.
• A significant 66% reduction in early-cycle VPCs (p < 0.001) observed 7-9 days after timolol initiation.
• A significant 73% reduction in early-cycle SVCs (p < 0.001) persisted throughout the 28-day study period.
• Significantly longer mean QRS duration in placebo-treated patients (p = 0.008).
• No difference in adverse effects between groups.

Conclusions:

• Timolol maleate demonstrates a delayed antiarrhythmic effect in acute myocardial infarction, specifically reducing early-cycle VPCs and SVCs.
• The drug appears safe for early administration in this patient population.
• Further research may explore optimal timing and duration for timolol use in AMI management.